Survival following IS taper and acyclovir in 11 renal transplantation patients with PTLD.

(A) Progression-free survival (PFS). (B) Overall survival (OS). Ten patients are alive and in CR, and 9 patients are progression-free with a median follow-up of 29 months. Patient no. 2 died shortly after diagnosis from overwhelming sepsis, and patient no. 6 relapsed twice after a complete response (CR) of 25 months but is again in CR.